Announcement on the 2019 profit distribution plan.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-005
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2019 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Distribution Ratio per Share: Cash Dividend 3.0 Yuan (Tax Included) for Every 10 Shares. No bonus shares will be distributed and no CPF capitalization will be made in 2019.
- This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
- If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
- Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2020, the company will accelerate the promotion of Guizhou peak daily production of 4500 tons of cement clinker new dry cement production line off-site technical transformation (with waste heat power generation) project, peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparation project, Anhui Zhongwang phase II technical transformation project, new Beika chemical technical transformation project and other projects under construction. In addition, Spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor drug "DPT" has entered the clinical stage, the need to increase research and development investment. The development of the above-mentioned business requires large financial support. The content of
1. profit distribution plan
was audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of the company in 2019 was ,724,688,055.43 yuan. The net profit of the parent company's accounting statement ,267,306,832.98 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 26,730,683.30 yuan, plus undistributed profit 1,014,878,186.69 yuan at the beginning of the year, minus 2018 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,152,229,187.97 yuan.
Company plans to make cash distribution in 2019 , based on ,344,083, 828 shares at the end of 2019 , with cash dividends 3.0 yuan (tax included) for every 10 shares, and the total cash dividends to all shareholders registered on the date of record are 103,225,148.40 yuan (tax included).
No CPF conversion to share capital in 2019 .
If the total share capital of the Company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the Company intends to maintain the distribution ratio per share and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.
This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. During the reporting period of
, the net profit attributable to the shareholders of the listed company in the consolidated statement of the company was 724,688,055.43
yuan, the accumulated undistributed profit of the parent company was1,152,229,187.97 yuan, and the total cash dividend to be distributed by the listed company was 103,225,148.40 yuan (including tax), the proportion of net profit attributable to shareholders of listed companies this year is lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development and has many construction projects. In 2020
, the company will continue to accelerate the construction of the project( estimated investment is 6.5 .2 billion ) of the new dry cement production line with a daily output of 4500 tons of cement clinker in Guizhou Huangping Jianfeng Cement Co., Ltd; the holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. Jinxi Production Base produces 20 .6 billion pieces of solid preparation project ( is expected to invest 50146 million yuan ) ; The holding subsidiary Anhui zhongwang pharmaceutical co., ltd. phase ii technological transformation project ( estimated total investment is 17500 .06 million yuan ) ; the construction and renovation of the technical renovation project ( is expected to invest 13274.25 .12 million yuan ) and other projects under construction by the end of 2019 , the above-mentioned projects have invested 4.91 .8 billion yuan. In addition, Jianfeng Pharmaceutical has a number of new drugs in various stages of research and development. The new anti-tumor drug "DPT " has entered the clinical stage. Jianfeng Pharmaceutical and its subsidiaries Zhejiang Erying Pharmaceutical Co., Ltd. and Zhejiang Jianfeng Yien Biotechnology Co., Ltd. will further increase product research and development and introduction, and need to increase research and development investment. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company
(I) the convening, deliberation and voting of the board meeting
2020
April# December August24 , the company held the 14th meeting of the 10th board of 131 by combining on-site and communication voting. the company currently has eight directors, all of whom attended the meeting in person, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2019 was deliberated and approved by 8 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2019 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting.
(II) Independent Director's OpinionThe independent director of the company expressed the following opinions on the company's 2019
annual profit distribution plan:1
, agreeing that the company will pay a cash dividend of 3.0
yuan (including tax) for every10 shares based on 2019 year-end share capital ,344,083, 828 shares, the total amount of cash dividends distributed to all shareholders registered on the date of record is 103,225,148.40 yuan (including tax), 2019 year will not be converted into share capital. , the profit distribution plan is based on the actual operating results and financial situation of the Company
2019, combined with the actual needs of the Company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3 , the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, convening and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's
2019Annual General Meeting for consideration. (III) the opinions of the board of supervisors
2020, the company held the 184 meeting of the 9th 183 of the 9th board of supervisors. the company currently has five supervisors, all of whom attended the meeting in person, which conforms to the relevant provisions of the company law and the articles of association, and the resolution made is legal and effective. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year 2019 was deliberated and approved with 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2019 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; No company profit distribution and cash dividend decisions were found to damage the legitimate rights and interests of shareholders.
4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2019
annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April
28, 2002
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page